Literature DB >> 20727040

Molecular underpinning of B-cell anergy.

Yuval Yarkoni1, Andrew Getahun, John C Cambier.   

Abstract

A byproduct of the largely stochastic generation of a diverse B-cell specificity repertoire is production of cells that recognize autoantigens. Indeed, recent studies indicate that more than half of the primary repertoire consists of autoreactive B cells that must be silenced to prevent autoimmunity. While this silencing can occur by multiple mechanisms, it appears that most autoreactive B cells are silenced by anergy, wherein they populate peripheral lymphoid organs and continue to express unoccupied antigen receptors yet are unresponsive to antigen stimulation. Here we review molecular mechanisms that appear operative in maintaining the antigen unresponsiveness of anergic B cells. In addition, we present new data indicating that the failure of anergic B cells to mobilize calcium in response to antigen stimulation is not mediated by inactivation of stromal interacting molecule 1, a critical intermediary in intracellular store depletion-induced calcium influx.

Entities:  

Mesh:

Year:  2010        PMID: 20727040      PMCID: PMC2968701          DOI: 10.1111/j.1600-065X.2010.00936.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  165 in total

1.  Different nuclear signals are activated by the B cell receptor during positive versus negative signaling.

Authors:  J I Healy; R E Dolmetsch; L A Timmerman; J G Cyster; M L Thomas; G R Crabtree; R S Lewis; C C Goodnow
Journal:  Immunity       Date:  1997-04       Impact factor: 31.745

2.  The SHIP phosphatase becomes associated with Fc gammaRIIB1 and is tyrosine phosphorylated during 'negative' signaling.

Authors:  D D'Ambrosio; D C Fong; J C Cambier
Journal:  Immunol Lett       Date:  1996-12       Impact factor: 3.685

3.  Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes.

Authors:  D A Nemazee; K Bürki
Journal:  Nature       Date:  1989-02-09       Impact factor: 49.962

4.  Structure and function of anti-DNA autoantibodies derived from a single autoimmune mouse.

Authors:  M J Shlomchik; A H Aucoin; D S Pisetsky; M G Weigert
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

5.  B-lymphocyte activation mediated by anti-immunoglobulin antibody in the absence of protein kinase C.

Authors:  J J Mond; N Feuerstein; F D Finkelman; F Huang; K P Huang; G Dennis
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

6.  Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice.

Authors:  C C Goodnow; J Crosbie; S Adelstein; T B Lavoie; S J Smith-Gill; R A Brink; H Pritchard-Briscoe; J S Wotherspoon; R H Loblay; K Raphael
Journal:  Nature       Date:  1988-08-25       Impact factor: 49.962

7.  Induction of self-tolerance in mature peripheral B lymphocytes.

Authors:  C C Goodnow; J Crosbie; H Jorgensen; R A Brink; A Basten
Journal:  Nature       Date:  1989-11-23       Impact factor: 49.962

8.  Differential activation of transcription factors induced by Ca2+ response amplitude and duration.

Authors:  R E Dolmetsch; R S Lewis; C C Goodnow; J I Healy
Journal:  Nature       Date:  1997-04-24       Impact factor: 49.962

9.  B lymphocyte antigen receptors (mIg) are non-covalently associated with a disulfide linked, inducibly phosphorylated glycoprotein complex.

Authors:  K S Campbell; J C Cambier
Journal:  EMBO J       Date:  1990-02       Impact factor: 11.598

10.  Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice.

Authors:  J Erikson; M Z Radic; S A Camper; R R Hardy; C Carmack; M Weigert
Journal:  Nature       Date:  1991-01-24       Impact factor: 49.962

View more
  55 in total

1.  TRAF3 Acts as a Checkpoint of B Cell Receptor Signaling to Control Antibody Class Switch Recombination and Anergy.

Authors:  Zhangguo Chen; Alexandra Krinsky; Rachel A Woolaver; Xiaoguang Wang; Samantha M Y Chen; Vince Popolizio; Ping Xie; Jing H Wang
Journal:  J Immunol       Date:  2020-06-26       Impact factor: 5.422

Review 2.  Historical overview of immunological tolerance.

Authors:  Ronald H Schwartz
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

3.  Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells.

Authors:  Anna Parente-Ribes; Sigrid S Skånland; Simone Bürgler; Audun Os; Dong Wang; Bjarne Bogen; Geir E Tjønnfjord; Kjetil Taskén; Ludvig A Munthe
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

Review 4.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

Review 5.  The multiple pathways to autoimmunity.

Authors:  Argyrios N Theofilopoulos; Dwight H Kono; Roberto Baccala
Journal:  Nat Immunol       Date:  2017-06-20       Impact factor: 25.606

Review 6.  Minding the gap: The impact of B-cell tolerance on the microbial antibody repertoire.

Authors:  Joel Finney; Akiko Watanabe; Garnett Kelsoe; Masayuki Kuraoka
Journal:  Immunol Rev       Date:  2019-09-27       Impact factor: 12.988

Review 7.  Malignant pirates of the immune system.

Authors:  Lixin Rui; Roland Schmitz; Michele Ceribelli; Louis M Staudt
Journal:  Nat Immunol       Date:  2011-09-20       Impact factor: 25.606

8.  A role for IRF8 in B cell anergy.

Authors:  Simanta Pathak; Shibin Ma; Vipul Shukla; Runqing Lu
Journal:  J Immunol       Date:  2013-11-11       Impact factor: 5.422

Review 9.  Targeting pathological B cell receptor signalling in lymphoid malignancies.

Authors:  Ryan M Young; Louis M Staudt
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

10.  Dok1 and Dok2 proteins regulate natural killer cell development and function.

Authors:  Javier Celis-Gutierrez; Marilyn Boyron; Thierry Walzer; Pier Paolo Pandolfi; Stipan Jonjić; Daniel Olive; Marc Dalod; Eric Vivier; Jacques A Nunès
Journal:  EMBO J       Date:  2014-06-24       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.